- AI
- Molecular Imaging
- CT
- X-Ray
- Ultrasound
- MRI
- Facility Management
- Mammography
Conductus ships first supercon probe
Conductus of Sunnyvale, CA, has made the first commercial shipmentof its SuperProtonnmr high-temperature superconducting probefor NMR spectroscopy. The probe, which is being distributed byVarian Associates as part of its Unity Inova spectrometer
Conductus of Sunnyvale, CA, has made the first commercial shipmentof its SuperProtonnmr high-temperature superconducting probefor NMR spectroscopy. The probe, which is being distributed byVarian Associates as part of its Unity Inova spectrometer system,was shipped to the National High Magnetic Field Lab at FloridaState University in Tallahassee.
SuperProtonnmr uses coils made of the high-temperaturesuperconductor yttrium barium copper oxide (SCAN 4/24/96). Conductusclaims that the probe is four times as sensitive as conventionalNMR probes, allowing the analysis of much smaller samples.
In other Conductus news, the company this month announced adistribution agreement with Nalorac, a Martinez, CA, manufacturerand distributor of NMR probes. The deal will expand the distributioncoverage available for Conductus' high-temperature superconductingprobes, as Nalorac supplies conventional NMR probes to all majorNMR manufacturers.
Can Portable Dual-Energy X-Ray be a Viable Alternative to CT in the ICU?
September 13th 2024The use of a portable dual-energy X-ray detector in the ICU at one community hospital reportedly facilitated a 37.5 percent decrease in chest CT exams in comparison to the previous three months, according to research presented at the American Society of Emergency Radiology (ASER) meeting in Washington, D.C.
New Meta-Analysis Examines MRI Assessment for Treatment of Esophageal Cancer
September 12th 2024Diffusion-weighted MRI provided pooled sensitivity and specificity rates of 82 percent and 81 percent respectively for gauging patient response to concurrent chemoradiotherapy for esophageal cancer, according to new meta-analysis.
Study for Emerging PET/CT Agent Reveals ‘New Standard’ for Detecting Clear Cell Renal Cell Carcinoma
September 11th 2024Results from a multicenter phase 3 trial showed that the PET/CT imaging agent (89Zr)Zr-girentuximab had an 85.5 percent mean sensitivity rate for the diagnosis of clear cell renal cell carcinoma.
Can Radiomics and Autoencoders Enhance Real-Time Ultrasound Detection of Breast Cancer?
September 10th 2024Developed with breast ultrasound data from nearly 1,200 women, a model with mixed radiomic and autoencoder features had a 90 percent AUC for diagnosing breast cancer, according to new research.
